clinical trial · NCT07006792
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Eli Lilly and Company·phase4·recruiting·n = 200
Atopic DermatitisLebrikizumab
brief summary
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
started
Jun 16, 2025
primary completion
Apr 1, 2026
completion
Sep 1, 2026
last updated
Apr 17, 2026
official title
A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol